CA2808016C - 6,7-disubstituted-isoquinoline derivatives and their use - Google Patents
6,7-disubstituted-isoquinoline derivatives and their use Download PDFInfo
- Publication number
- CA2808016C CA2808016C CA2808016A CA2808016A CA2808016C CA 2808016 C CA2808016 C CA 2808016C CA 2808016 A CA2808016 A CA 2808016A CA 2808016 A CA2808016 A CA 2808016A CA 2808016 C CA2808016 C CA 2808016C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- formula
- compounds
- pharmaceutically acceptable
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
Abstract
The present invention relates compounds of general formula (I) and stereoisomers and pharmaceutically acceptable salts and prodrugs thereof; wherein R' and R1 - R5 are as defined in the claims. The invention also relates to said compounds for use as a medicament and particularly in the treatment of drug addiction and CNS related diseases.
Description
6,7-DISUBSTITUTED-ISOQUINOLINE DERIVATIVES AND THEIR USE
FIELD OF THE INVENTION
The present invention relates to novel 6,7-disubstituted-isoquinoline derivatives and more particularly to novel 6,7-disubstituted-1-methyl-1,2,3,4-tetrahydro- and -3,4-dihydroisoquinoline derivatives and pharmaceutical compositions comprising them. The invention also relates to said compounds for use in the treatment of drug addiction and CNS related diseases.
BACKGROUND OF THE INVENTION
Endogenous isoquinolines are formed by condensation of biogenic amines ¨ such as phenethylamine ¨ and simple aldehydes, such as formal-dehyde or acetaldehyde. They are known to modulate neurotransmission, central metabolism and motor activity. An endogenous TIQ derivative salsolinol (1-methyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol) is considered to be a caus-ative factor of Parkinson's disease (PD), while (R)-1-MeTIQ (1-methyl-1,2,3,4-tetrahydroisoquinoline) was shown to possess an antiparkinsonian activity.
Until recently 1MeTIQ was the only known neuroprotective/PD preventing TIQ
derivative. In 2006 Katsuhiro OKUDA et al. (Biological and Pharmaceutical Bulletin 29 (2006) pp. 1401-1403) discovered that 5/647-monohydroxylated 1MeTIQ derivatives are neuroprotective and PD preventing indeed, even more so than the parent compound.
It has been demonstrated that concentrations of many endogenous TIQ derivatives are significantly elevated in the urine and cerebrospinal fluid of PD/ADHD (attention deficit hyperactivity disorder) patients compared to controls, the content of 1MeTIQ however is significantly decreased in, PD
patients' cerebrospinal fluid and brain.
Salsolinol is formed enzymatically as well as non-enzymatically as a condensation product of acetaldehyde ¨ the primary metabolite of ethanol ¨
with dopamine in the brain of mammals. Salsolinol affects the uptake of catecholamines into nerve terminals, the release of stored catecholamines and the activity of monoamine oxidase (MAO), catechol-O-methyl transferase (COMT) and tyrosine hydroxylase. Ethanol induced elevation of salsolinol levels is known to participate in the development of ethanol addiction/alco-holism.
FIELD OF THE INVENTION
The present invention relates to novel 6,7-disubstituted-isoquinoline derivatives and more particularly to novel 6,7-disubstituted-1-methyl-1,2,3,4-tetrahydro- and -3,4-dihydroisoquinoline derivatives and pharmaceutical compositions comprising them. The invention also relates to said compounds for use in the treatment of drug addiction and CNS related diseases.
BACKGROUND OF THE INVENTION
Endogenous isoquinolines are formed by condensation of biogenic amines ¨ such as phenethylamine ¨ and simple aldehydes, such as formal-dehyde or acetaldehyde. They are known to modulate neurotransmission, central metabolism and motor activity. An endogenous TIQ derivative salsolinol (1-methyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol) is considered to be a caus-ative factor of Parkinson's disease (PD), while (R)-1-MeTIQ (1-methyl-1,2,3,4-tetrahydroisoquinoline) was shown to possess an antiparkinsonian activity.
Until recently 1MeTIQ was the only known neuroprotective/PD preventing TIQ
derivative. In 2006 Katsuhiro OKUDA et al. (Biological and Pharmaceutical Bulletin 29 (2006) pp. 1401-1403) discovered that 5/647-monohydroxylated 1MeTIQ derivatives are neuroprotective and PD preventing indeed, even more so than the parent compound.
It has been demonstrated that concentrations of many endogenous TIQ derivatives are significantly elevated in the urine and cerebrospinal fluid of PD/ADHD (attention deficit hyperactivity disorder) patients compared to controls, the content of 1MeTIQ however is significantly decreased in, PD
patients' cerebrospinal fluid and brain.
Salsolinol is formed enzymatically as well as non-enzymatically as a condensation product of acetaldehyde ¨ the primary metabolite of ethanol ¨
with dopamine in the brain of mammals. Salsolinol affects the uptake of catecholamines into nerve terminals, the release of stored catecholamines and the activity of monoamine oxidase (MAO), catechol-O-methyl transferase (COMT) and tyrosine hydroxylase. Ethanol induced elevation of salsolinol levels is known to participate in the development of ethanol addiction/alco-holism.
2 Salsolinol (SAL) has been postulated to mediate some of the addictive properties of alcohol. A number of studies have shown that primates self-administer SAL even in nanomolar concentrations when intracranially injected to certain brain region. Also acetaldehyde is self-administered when injected intracranially although much higher concentrations are needed.
Studies have confirmed that SAL is released during suckling on lactating sheep. It is clear that SAL mediates reinforcing effects on a number of primate species. Studies have shown that controlled amounts of ethanol intake have only miniscule effect on brain SAL levels. Still it is clear that ethanol intake elevates dopamine and acetaldehyde concentrations inside brain and so the concentrations of starting materials for Pictet-Spengler reaction forming SAL
are elevated. In this light it seems certain that alcoholics with higher ethanol intake and generally higher aldehyde dehydrogenase (ALDH) activity (see Alcohol Clin. Exp. Res. 2009 Nov.; 33(11):1935-44) try to compensate lower acetaldehyde and SAL concentrations by increased drinking.
Most tetrahydroisoquinolines penetrate to the brain in pharma-cologically relevant amounts and induce a variety of effects. Most of the TIQ
and 1MeTIQ exit the brain (90.4% and 95.3%) and is excreted in urine (76%
and 72%) unchanged. The hydroxylated (C4 of the isoquinoline backbone) derivatives of TIQ and 1MeTIQ were the most abundant metabolites in the urine (2.7% 8.7%).
In European Journal of Medicinal Chemistry 41 (2006) pp. 241-252 6-fluoro-1-methyl-1,2,3,4-tetrahydroisoquinoline has been reported as a poss-ible agent against Parkinson's disease.
EP 2 090 576 A1 discloses certain 5,8- and 6,7-difluoro substituted isoquinolines as intermediates in the preparation of pyrazolo[1,5-a]pyridines for use as metabotropic glutamate receptor modulators.
It has now surprisingly been found that the substitution of 6- and 7-positions of the isoquinoline backbone blocks the adverse metabolic formation of dihydroxy compounds and thereby also improves the desired activity of the isoquinoline compound in question.
Studies have confirmed that SAL is released during suckling on lactating sheep. It is clear that SAL mediates reinforcing effects on a number of primate species. Studies have shown that controlled amounts of ethanol intake have only miniscule effect on brain SAL levels. Still it is clear that ethanol intake elevates dopamine and acetaldehyde concentrations inside brain and so the concentrations of starting materials for Pictet-Spengler reaction forming SAL
are elevated. In this light it seems certain that alcoholics with higher ethanol intake and generally higher aldehyde dehydrogenase (ALDH) activity (see Alcohol Clin. Exp. Res. 2009 Nov.; 33(11):1935-44) try to compensate lower acetaldehyde and SAL concentrations by increased drinking.
Most tetrahydroisoquinolines penetrate to the brain in pharma-cologically relevant amounts and induce a variety of effects. Most of the TIQ
and 1MeTIQ exit the brain (90.4% and 95.3%) and is excreted in urine (76%
and 72%) unchanged. The hydroxylated (C4 of the isoquinoline backbone) derivatives of TIQ and 1MeTIQ were the most abundant metabolites in the urine (2.7% 8.7%).
In European Journal of Medicinal Chemistry 41 (2006) pp. 241-252 6-fluoro-1-methyl-1,2,3,4-tetrahydroisoquinoline has been reported as a poss-ible agent against Parkinson's disease.
EP 2 090 576 A1 discloses certain 5,8- and 6,7-difluoro substituted isoquinolines as intermediates in the preparation of pyrazolo[1,5-a]pyridines for use as metabotropic glutamate receptor modulators.
It has now surprisingly been found that the substitution of 6- and 7-positions of the isoquinoline backbone blocks the adverse metabolic formation of dihydroxy compounds and thereby also improves the desired activity of the isoquinoline compound in question.
3 SUMMARY OF THE INVENTION
The present invention relates to novel compounds of general formula (I) Ri and stereoisomers and pharmaceutically acceptable salts and prodrugs thereof;
wherein the dotted line represents an optional bond;
R' is H, or R' is absent, when the dotted line represent a bond;
R1 and R4 are each independently selected from the group consisting of H, halo, lower alkyl, trifluoromethyl and trifluoromethoxy;
R2 and R3 are both F, or one of R2 and R3 is F and the other is lower alkyl or trifluoromethyl; and R5 is selected from the group consisting of halo, lower alkyl, trifluoromethyl and trifluoromethoxy, or when the dotted line represents a bond, and then R5 may also be H.
According to one aspect of the invention, there is provided a compound of general formula (I) ,-NR' RRi or stereoisomers or pharmaceutically acceptable salts thereof;
wherein the dotted line represents an optional bond;
R' is H, or R' is absent, when the dotted line represent a bond;
R1 and R4 are each independently selected from the group consisting of H, halo, Ci-C6-alkyl, trifluoromethyl and trifluoromethoxy;
R2 and R3 are both F, or one of R2 and R3 is F and the other is Cr C6-alkyl or trifluoromethyl; and 3a R5 is selected from the group consisting of halo, C1-C6-alkyl, trifluoromethyl and trifluoromethoxy, or when the dotted line represents a bond, then R5 may also be H.
The invention also relates to a pharmaceutical composition comprising an effective amount of one or more compounds of formula (I) or stereoisomers or pharmaceutical acceptable salts thereof and a pharma-ceutically acceptable carrier and suitable excipients.
Further, the invention relates to compounds of formula (I) or stereo-isomers or pharmaceutically acceptable salts thereof for use as a medicament.
The invention also relates to compounds of formula (I) or stereo-isomers or pharmaceutically acceptable salts thereof for use in the treatment of drug addiction, alcoholism, anorexia, bulimia, and CNS related diseases.
DETAILED DESCRIPTION OF THE INVENTION
In the definition of the compound group of formula (I) according to the invention the term "halo" refers to F, Cl, I and Br, preferably F. By the term "lower alkyl" is meant saturated branched or linear hydrocarbons containing 1 -carbon atoms, preferably 1 - 3 carbon atoms, especially methyl or ethyl.
Examples of preferred compounds of formula (I) are those where the dotted line represents a bond. Among these compounds preferred com-
The present invention relates to novel compounds of general formula (I) Ri and stereoisomers and pharmaceutically acceptable salts and prodrugs thereof;
wherein the dotted line represents an optional bond;
R' is H, or R' is absent, when the dotted line represent a bond;
R1 and R4 are each independently selected from the group consisting of H, halo, lower alkyl, trifluoromethyl and trifluoromethoxy;
R2 and R3 are both F, or one of R2 and R3 is F and the other is lower alkyl or trifluoromethyl; and R5 is selected from the group consisting of halo, lower alkyl, trifluoromethyl and trifluoromethoxy, or when the dotted line represents a bond, and then R5 may also be H.
According to one aspect of the invention, there is provided a compound of general formula (I) ,-NR' RRi or stereoisomers or pharmaceutically acceptable salts thereof;
wherein the dotted line represents an optional bond;
R' is H, or R' is absent, when the dotted line represent a bond;
R1 and R4 are each independently selected from the group consisting of H, halo, Ci-C6-alkyl, trifluoromethyl and trifluoromethoxy;
R2 and R3 are both F, or one of R2 and R3 is F and the other is Cr C6-alkyl or trifluoromethyl; and 3a R5 is selected from the group consisting of halo, C1-C6-alkyl, trifluoromethyl and trifluoromethoxy, or when the dotted line represents a bond, then R5 may also be H.
The invention also relates to a pharmaceutical composition comprising an effective amount of one or more compounds of formula (I) or stereoisomers or pharmaceutical acceptable salts thereof and a pharma-ceutically acceptable carrier and suitable excipients.
Further, the invention relates to compounds of formula (I) or stereo-isomers or pharmaceutically acceptable salts thereof for use as a medicament.
The invention also relates to compounds of formula (I) or stereo-isomers or pharmaceutically acceptable salts thereof for use in the treatment of drug addiction, alcoholism, anorexia, bulimia, and CNS related diseases.
DETAILED DESCRIPTION OF THE INVENTION
In the definition of the compound group of formula (I) according to the invention the term "halo" refers to F, Cl, I and Br, preferably F. By the term "lower alkyl" is meant saturated branched or linear hydrocarbons containing 1 -carbon atoms, preferably 1 - 3 carbon atoms, especially methyl or ethyl.
Examples of preferred compounds of formula (I) are those where the dotted line represents a bond. Among these compounds preferred com-
4 pounds are those where R1, R2 and R3 are H. Further preferred compounds are those where R1 and R2 are H and R3 is F or methyl. Preferred specific compounds are 6,7-difluoro-1-methy1-3,4-dihydroisoquinoline, 1-methy1-4,6,7-trifluoro-3,4-dihydroisoquinoline, 4,6,7-trifuoro-1 -methyl-1 ,2,3,4-tetrahydroisoqu inoline, 4,6-difluoro-1,7-dimethy1-3,4-dihydroisoquinoline,and pharmaceutically acceptable salts and prodrugs thereof.
Typical pharmaceutically acceptable salts are acid addition salts 113 formed with inorganic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like, and salts formed with organic acids, such as acetic acid, oxalic acid, tartaric acid, succinic acid, nnalic acid, fumaric acid, maleic acid, ascorbic acid, benzoic acid and the like.
Pharmaceutically acceptable salts also include alkali metal salts, (e.g.
sodium and potassium), alkaline earth metal salts (e.g. calcium or magnesium), aluminium salts, ammonium salts and salts with organic amines such as with methylamine, dimethylamine, trimethylamine, ethylamine, triethylamine, morpholine, and the like.
Pharmaceutical compositions comprising one or more compounds of the invention may further contain conventional carriers, diluents or excipients and may be administered in a solid dosage form, such as tablets or capsules, or in a liquid form, such as solutions, suspensions, emulsions, elixirs, for oral use, or in the form of sterile injectable solutions for parenteral use.
Solid dosage forms may additionally include, e.g., binders, such as microcrystalline cellulose, gum tragacanth or gelatine; excipients, such as starch or lactose, disintegrating agent, such as alginic acid or corn starch;
lubricants, such as magnesium stearate; glidants, such as colloidal silicon dioxide; and sweeteners and flavoring agents and like. Liquid dosage forms suitable for oral administration may include a suitable aqueous or non-aqueous vehicle with buffers, suspending and dispensing agents, colorants, flavors and the like. For parenteral use, compositions are formed in sterile saline or phosphate buffered saline or other injectable vehicles known in the art.
Such pharmaceutical compositions and dosage forms contain a compound of the invention in an amount effective for the desired purpose. The effective amount will typically be determined by a physician, and depend on the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and like.
Endogenous isoquinolines are compounds which are formed by condensation of biogenic amines and simple aldehydes such as formaldehyde
Typical pharmaceutically acceptable salts are acid addition salts 113 formed with inorganic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like, and salts formed with organic acids, such as acetic acid, oxalic acid, tartaric acid, succinic acid, nnalic acid, fumaric acid, maleic acid, ascorbic acid, benzoic acid and the like.
Pharmaceutically acceptable salts also include alkali metal salts, (e.g.
sodium and potassium), alkaline earth metal salts (e.g. calcium or magnesium), aluminium salts, ammonium salts and salts with organic amines such as with methylamine, dimethylamine, trimethylamine, ethylamine, triethylamine, morpholine, and the like.
Pharmaceutical compositions comprising one or more compounds of the invention may further contain conventional carriers, diluents or excipients and may be administered in a solid dosage form, such as tablets or capsules, or in a liquid form, such as solutions, suspensions, emulsions, elixirs, for oral use, or in the form of sterile injectable solutions for parenteral use.
Solid dosage forms may additionally include, e.g., binders, such as microcrystalline cellulose, gum tragacanth or gelatine; excipients, such as starch or lactose, disintegrating agent, such as alginic acid or corn starch;
lubricants, such as magnesium stearate; glidants, such as colloidal silicon dioxide; and sweeteners and flavoring agents and like. Liquid dosage forms suitable for oral administration may include a suitable aqueous or non-aqueous vehicle with buffers, suspending and dispensing agents, colorants, flavors and the like. For parenteral use, compositions are formed in sterile saline or phosphate buffered saline or other injectable vehicles known in the art.
Such pharmaceutical compositions and dosage forms contain a compound of the invention in an amount effective for the desired purpose. The effective amount will typically be determined by a physician, and depend on the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and like.
Endogenous isoquinolines are compounds which are formed by condensation of biogenic amines and simple aldehydes such as formaldehyde
5 or acetaldehyde. The compounds of the invention can be synthesized using well documented reactions and commercially available starting materials. We have explored a series of new TIQ derivatives primarily targeted to mimic the actions of 1MeTIQ and also SAL to some extent. These novel 1MeTIQ
compounds can be used to achieve many desirable pharmacological responses. Fluorination can alter the bond strength, lipophilicity, conformation, electrostatic potential, dipoles, and pKa.
Substitution, especially fluorination, at the position of metabolic attack ¨ mainly at positions 6, 7 and 4 ¨ is used to alter the route and rate of metabolic degradation. Fluorination may also alter the tissue distribution, pharmacodynamics and toxicology of the compound. It can be generalized that replacing hydrogen with fluorine causes minimal steric effects at the receptor.
By replacing both of the catechol hydroxyls of SAL, especially with fluorine, a better targeting of the drug distribution and smaller active dosages are achieved. Unlike SAL, the compounds of the present invention are actively transported over the blood brain barrier by organic cation transporters and are concentrated in the brain. Most of the compounds of the present invention cannot be oxidized to form epoxides thereby making them less prone to cause oxidative stress. The compounds of the invention are associated with neuro-protective and neuroregenerative properties instead of neurotoxicity or neuro-degeneration, which is the case with SAL. Further, the novel compounds are better in mimicking desirable effects of SAL and treating alcoholism and Parkinson's disease than e.g. 6-monofluorinated TIQ.
The novel compounds according to the invention are structurally related to 1MeTIQ. Thus, the novel compounds can be used, in addition to the treatment of e.g. Alzheimer's disease and Parkinson's disease, to treat addictions in general ¨ from alcohol to cocaine and heroin. Number of positive pharmacological responses can be achieved simultaneously. While decreasing the tendency to relapse and likelihood of developing an addiction, these compounds can act as general mood stabilizers and general neuroprotectants possessing remarkable antiparkinsonian and antiepileptic character.
compounds can be used to achieve many desirable pharmacological responses. Fluorination can alter the bond strength, lipophilicity, conformation, electrostatic potential, dipoles, and pKa.
Substitution, especially fluorination, at the position of metabolic attack ¨ mainly at positions 6, 7 and 4 ¨ is used to alter the route and rate of metabolic degradation. Fluorination may also alter the tissue distribution, pharmacodynamics and toxicology of the compound. It can be generalized that replacing hydrogen with fluorine causes minimal steric effects at the receptor.
By replacing both of the catechol hydroxyls of SAL, especially with fluorine, a better targeting of the drug distribution and smaller active dosages are achieved. Unlike SAL, the compounds of the present invention are actively transported over the blood brain barrier by organic cation transporters and are concentrated in the brain. Most of the compounds of the present invention cannot be oxidized to form epoxides thereby making them less prone to cause oxidative stress. The compounds of the invention are associated with neuro-protective and neuroregenerative properties instead of neurotoxicity or neuro-degeneration, which is the case with SAL. Further, the novel compounds are better in mimicking desirable effects of SAL and treating alcoholism and Parkinson's disease than e.g. 6-monofluorinated TIQ.
The novel compounds according to the invention are structurally related to 1MeTIQ. Thus, the novel compounds can be used, in addition to the treatment of e.g. Alzheimer's disease and Parkinson's disease, to treat addictions in general ¨ from alcohol to cocaine and heroin. Number of positive pharmacological responses can be achieved simultaneously. While decreasing the tendency to relapse and likelihood of developing an addiction, these compounds can act as general mood stabilizers and general neuroprotectants possessing remarkable antiparkinsonian and antiepileptic character.
6 The compounds exhibit many pharmacological responses, such as - prolonging the duration of morphine without enhancing the peak action - antagonizing the development of morphine tolerance - reducing the naloxone-precipitated withdrawal symptoms - inhibiting the reinstatement of cocaine self-administration - attenuating cravings - inhibiting the activity of monoamine-oxidases (MA0s) - inhibiting the activity of acetylcholinesterase (ACE) - neuroprotection - shifting the catabolism of catecholamine neurotransmitters towards catechol-O-methyl transferase (COMT) -dependent methylation - inhibition or enhancement of the release of prolactin - releasing norepinephrine - inducing or inhibiting neuron related apoptosis and/or necrosis - abolishing cocaine induced inhibition of noradrenalin metabolism.
The compounds according to the present invention may be prepared by processes known per se as follows.
Step 1. Knoevenagel Condensation ¨ Tet. Lett. 39, 8013-8016 (1998):
1.0 mol eq. subst. benzaldehyde, 1.2 mol eq. nitromethane, 0.47 mol eq. ammonium acetate and 0.35 mol eq. glacial acetic acid (GAA) was sonicated (40kHz) at RT for 3 h. After removal of nitromethane, partition between dichloromethane and water then brine gave a crude product which was recrystallized from aq, (m)ethanol or AcOH; or 1.0 mol eq. subst. benzaldehyde, 1.2 mol eq. nitromethane and 0.1 mol eq. cyclohexylamine was mixed and kept in dark for 4 weeks, or until H20 formation ceased. The crude product was ground, washed with brine and recrystallized from aq. (m)ethanol or AcOH; or in the case of R5 halogen substitution (preferably fluorine), the synthesis proceeds via nitroalcohol intermediate, otherwise skip to step 4:
1.0 mol eq. subst. benzaldehyde, with 1.0 mol eq. of triethylamine and 1.2 mol eq. nitromethane was stirred in methanol at -12 C for 21/2 h, and the amine quenched with 1.0 mol eq. of GAA while still freezing cold. Most of the solvent was stripped under vacuum, and the remains were dissolved in
The compounds according to the present invention may be prepared by processes known per se as follows.
Step 1. Knoevenagel Condensation ¨ Tet. Lett. 39, 8013-8016 (1998):
1.0 mol eq. subst. benzaldehyde, 1.2 mol eq. nitromethane, 0.47 mol eq. ammonium acetate and 0.35 mol eq. glacial acetic acid (GAA) was sonicated (40kHz) at RT for 3 h. After removal of nitromethane, partition between dichloromethane and water then brine gave a crude product which was recrystallized from aq, (m)ethanol or AcOH; or 1.0 mol eq. subst. benzaldehyde, 1.2 mol eq. nitromethane and 0.1 mol eq. cyclohexylamine was mixed and kept in dark for 4 weeks, or until H20 formation ceased. The crude product was ground, washed with brine and recrystallized from aq. (m)ethanol or AcOH; or in the case of R5 halogen substitution (preferably fluorine), the synthesis proceeds via nitroalcohol intermediate, otherwise skip to step 4:
1.0 mol eq. subst. benzaldehyde, with 1.0 mol eq. of triethylamine and 1.2 mol eq. nitromethane was stirred in methanol at -12 C for 21/2 h, and the amine quenched with 1.0 mol eq. of GAA while still freezing cold. Most of the solvent was stripped under vacuum, and the remains were dissolved in
7 dichloromethane (DCM) and washed two times with water and once with brine.
The DCM was stripped, leaving behind the crude nitroalcohol.
Step 2. (in the case of R5 halogen substitution) Sulfonating the aliphatic OH-group to appropriate sulfonyl ester by stirring 1.0 mol eq. of subst.
phenyl-2-amine-1-ol in DCM with 1.2 mol eq. of triethylamine (or using pyridine for the solvent) with and adding slowly 1.1 mol eq. of methylsulfonyl chloride maintaining the temperature at -5 C until conversion was complete. The product was washed several times with brine, dried over anhydrous MgSO4 and concentrated in vacuo.
Step 3. (in the case of R5 halogen substitution) Modified Finkelstein reaction to the sulfonate ester with potassium halide (in this case KF) proceeded by dissolving 1 mol eq. of sulfonyl-intermediate from the step 2 with 6 ml of acetonitrile per gram of substrate, 0.5 mol eq. of 1-buty1-3-methyl-imidazolium tetrafluoroborate and 5 mol eq. of H20 which after 1.05 mol eq.
amount of KF was added and the solution was mixed and sonicated at RT for 180 min or until TLC showed completion. The R5-halogen substituted compounds were then extracted with DCM and washed several times with brine, dried over anhydrous Mg504 and concentrated in vacuo prior pro-ceeding.
Step 4. Reduction of the possible C=C bond and nitro-group to the amino-group according to procedures well known in the art.
Step 5. Pictet-Spengler reaction - industrial scale (EP 0929527):
1.0 mol eq. subst. N-tosyl-phenethylamine and 3.0 mol eq. boron trifluoroetherate was refluxed with 21.0 mol eq. of 1,1-diethoxyethane for 12 h in N2 atmosphere or until TLC showed completion. The nitrogen is afterwards de-protected; or 1.0 mol eq. subst. phenethylamine was refluxed for 1h with 3.0 mol eq. acetaldehyde which after 1.2 mol eq. hydrochloric acid 37% was added and refluxing was continued until TLC showed completion.
Step 6. Workup The reaction mixture was partitioned between ethyl acetate (10 ml /
1 g substrate) and water (10 ml / 1 g substrate), separated, and the organic layer was washed twice with saturated sodium bicarbonate and dried over sodium sulfate (Na2504). The drying agent was filtered off and the filtrate was distilled under reduced pressure to yield the desired compound.
The DCM was stripped, leaving behind the crude nitroalcohol.
Step 2. (in the case of R5 halogen substitution) Sulfonating the aliphatic OH-group to appropriate sulfonyl ester by stirring 1.0 mol eq. of subst.
phenyl-2-amine-1-ol in DCM with 1.2 mol eq. of triethylamine (or using pyridine for the solvent) with and adding slowly 1.1 mol eq. of methylsulfonyl chloride maintaining the temperature at -5 C until conversion was complete. The product was washed several times with brine, dried over anhydrous MgSO4 and concentrated in vacuo.
Step 3. (in the case of R5 halogen substitution) Modified Finkelstein reaction to the sulfonate ester with potassium halide (in this case KF) proceeded by dissolving 1 mol eq. of sulfonyl-intermediate from the step 2 with 6 ml of acetonitrile per gram of substrate, 0.5 mol eq. of 1-buty1-3-methyl-imidazolium tetrafluoroborate and 5 mol eq. of H20 which after 1.05 mol eq.
amount of KF was added and the solution was mixed and sonicated at RT for 180 min or until TLC showed completion. The R5-halogen substituted compounds were then extracted with DCM and washed several times with brine, dried over anhydrous Mg504 and concentrated in vacuo prior pro-ceeding.
Step 4. Reduction of the possible C=C bond and nitro-group to the amino-group according to procedures well known in the art.
Step 5. Pictet-Spengler reaction - industrial scale (EP 0929527):
1.0 mol eq. subst. N-tosyl-phenethylamine and 3.0 mol eq. boron trifluoroetherate was refluxed with 21.0 mol eq. of 1,1-diethoxyethane for 12 h in N2 atmosphere or until TLC showed completion. The nitrogen is afterwards de-protected; or 1.0 mol eq. subst. phenethylamine was refluxed for 1h with 3.0 mol eq. acetaldehyde which after 1.2 mol eq. hydrochloric acid 37% was added and refluxing was continued until TLC showed completion.
Step 6. Workup The reaction mixture was partitioned between ethyl acetate (10 ml /
1 g substrate) and water (10 ml / 1 g substrate), separated, and the organic layer was washed twice with saturated sodium bicarbonate and dried over sodium sulfate (Na2504). The drying agent was filtered off and the filtrate was distilled under reduced pressure to yield the desired compound.
8 The method of preparing 3,4-dihydroisoquinolines from 1,2,3,4-tetrahydroisoquinolines is well known and also described in US Patent No.
6 034 094.
The pharmaceutically acceptable salts of the compounds of formula (I) may be prepared by conventional processes well-known to the person skilled in the art. For the preparation of pharmaceutical compositions and dosage forms as well as the carriers, diluents and expedients used in the preparation, see, for example, Remington's Pharmaceutical Sciences, 20th Edition, 2000, Marck Publishing Company, Easton, Pennsylvania.
The pharmacological activity of the compounds of the invention can be verified by methods known in the art. For example, the reducing effect on alcohol seeking behavior can be verified using the procedure described by Heidbreder, C.A., et al., Addict Biol. 2007 Mar;12(1):35-50. The parkinsonisnn-preventing activity can be shown, for example, as described by Okuda, K., et al. Biol Pharnn Bull. 2006 Jul;29(7):1401-1403.
The following specific non-limiting examples will further identify the compounds of the invention.
Example 1 6,7-difluoro-1-methyl-3,4-dihydroisoquinoline 1H NMR (CDCI3): 6 ppm 7.450 (3, 1H, d, J=4.858), 2.277 (6, 3H), 3.647 (8, 1H, ddd, J=13.253, J=9.980, J=3.970), 3.848 (8, 1H, ddd, J=13.253, J=3.860, J=1.950), 3.019 (9, 1H, ddd, J=14.326, J=3.970, J=1.950), 2.849 (9, 1H, ddd, J=14.326, J=9.980, J=3.860), 7.260 (11, 1H, d, J=4.858). B.P. 112-116 C at 10 mmHg.
Example 2 1-methyl-4,6,7-trifluoro-3,4-dihydroisoquinoline 1H NMR (CDCI3): 6 ppm 7.493 (3, 1H, d, J=5.422), 2.238 (6, 3H), 3.886 (8, 1H, dd, J=13.927, J=3.970), 3.943 (8, 1H, dd, J=13.927, J=1.960), 5.884 (9, 1H, dd, J=3.970, J=1.960), 7.763 (12, 1H, d, J=5.422). B.P. 118-122 C at 10 mmHg.
6 034 094.
The pharmaceutically acceptable salts of the compounds of formula (I) may be prepared by conventional processes well-known to the person skilled in the art. For the preparation of pharmaceutical compositions and dosage forms as well as the carriers, diluents and expedients used in the preparation, see, for example, Remington's Pharmaceutical Sciences, 20th Edition, 2000, Marck Publishing Company, Easton, Pennsylvania.
The pharmacological activity of the compounds of the invention can be verified by methods known in the art. For example, the reducing effect on alcohol seeking behavior can be verified using the procedure described by Heidbreder, C.A., et al., Addict Biol. 2007 Mar;12(1):35-50. The parkinsonisnn-preventing activity can be shown, for example, as described by Okuda, K., et al. Biol Pharnn Bull. 2006 Jul;29(7):1401-1403.
The following specific non-limiting examples will further identify the compounds of the invention.
Example 1 6,7-difluoro-1-methyl-3,4-dihydroisoquinoline 1H NMR (CDCI3): 6 ppm 7.450 (3, 1H, d, J=4.858), 2.277 (6, 3H), 3.647 (8, 1H, ddd, J=13.253, J=9.980, J=3.970), 3.848 (8, 1H, ddd, J=13.253, J=3.860, J=1.950), 3.019 (9, 1H, ddd, J=14.326, J=3.970, J=1.950), 2.849 (9, 1H, ddd, J=14.326, J=9.980, J=3.860), 7.260 (11, 1H, d, J=4.858). B.P. 112-116 C at 10 mmHg.
Example 2 1-methyl-4,6,7-trifluoro-3,4-dihydroisoquinoline 1H NMR (CDCI3): 6 ppm 7.493 (3, 1H, d, J=5.422), 2.238 (6, 3H), 3.886 (8, 1H, dd, J=13.927, J=3.970), 3.943 (8, 1H, dd, J=13.927, J=1.960), 5.884 (9, 1H, dd, J=3.970, J=1.960), 7.763 (12, 1H, d, J=5.422). B.P. 118-122 C at 10 mmHg.
9 Example 3 4,6,7-trifluoro-1-methyl-1,2,3,4-tetrahydroisoquinoline 1H NMR (CDCI3): 6 ppm 7.466 (3, 1H, d, J=5.020), 3.930 (5, 1H, q, J=6.684), 1.213 (6, 3H, d, J=6.684), 3.065 (8, 1H, dd, J=14.188, J=3.650), 3.089 (8, 1H, dd, J=14.188, J=2.050), 5.788 (9, 1H, dd, J=3.650, J=2.050), 7.602 (12, 1H, d, J=5.020). B.P. 108-113 C at 10 mmHg.
Example 4 4,7,8-trifluoro-1-methyl-6-(trifluoromethyl)-3,4-dihydroisoquinoline 1H NMR (CDCI3): 6 ppm 2.126 (1, 3H), 7.417 (8, 1H), 3.713 (9, 1H, dd, J=13.900, J=9.980), 4.072 (9, 1H, dd, J=13.900, J=3.860), 5.690 (17, 1H, dd, J=9.980, J=3.860). B.P. 133-137 at 10 mmHg.
Example 5 4,6-difluoro-1,7-dimethy1-3,4-dihydroisoquinoline 1H NMR (CDCI3): 6 ppm 2.242 (1, 3H), 2.326 (2, 3H), 7.350 (5, 1H, d, J=4.325), 7.626 (6, 1H, d, J=4.325), 3.668 (7, 1H, dd, J=14.314, J=9.980), 4.011 (7, 1H, dd, J=14.314, J=3.860), 5.875 (14, 1H, dd, J=9.980, J=3.860) B.P. 135-140 at 10 mmHg.
Example 4 4,7,8-trifluoro-1-methyl-6-(trifluoromethyl)-3,4-dihydroisoquinoline 1H NMR (CDCI3): 6 ppm 2.126 (1, 3H), 7.417 (8, 1H), 3.713 (9, 1H, dd, J=13.900, J=9.980), 4.072 (9, 1H, dd, J=13.900, J=3.860), 5.690 (17, 1H, dd, J=9.980, J=3.860). B.P. 133-137 at 10 mmHg.
Example 5 4,6-difluoro-1,7-dimethy1-3,4-dihydroisoquinoline 1H NMR (CDCI3): 6 ppm 2.242 (1, 3H), 2.326 (2, 3H), 7.350 (5, 1H, d, J=4.325), 7.626 (6, 1H, d, J=4.325), 3.668 (7, 1H, dd, J=14.314, J=9.980), 4.011 (7, 1H, dd, J=14.314, J=3.860), 5.875 (14, 1H, dd, J=9.980, J=3.860) B.P. 135-140 at 10 mmHg.
Claims (10)
1. A compound of general formula (I) or stereoisomers or pharmaceutically acceptable salts thereof;
wherein the dotted line represents an optional bond;
R' is H, or R' is absent, when the dotted line represent a bond;
R1 and R4 are each independently selected from the group consisting of H, halo, C1-C6-alkyl, trifluoromethyl and trifluoromethoxy;
R2 and R3 are both F, or one of R2 and R3 is F and the other is C1-C6-alkyl or trifluoromethyl; and R5 is selected from the group consisting of halo, C1-C6-alkyl, trifluoromethyl and trifluoromethoxy, or when the dotted line represents a bond, then R5 may also be H.
wherein the dotted line represents an optional bond;
R' is H, or R' is absent, when the dotted line represent a bond;
R1 and R4 are each independently selected from the group consisting of H, halo, C1-C6-alkyl, trifluoromethyl and trifluoromethoxy;
R2 and R3 are both F, or one of R2 and R3 is F and the other is C1-C6-alkyl or trifluoromethyl; and R5 is selected from the group consisting of halo, C1-C6-alkyl, trifluoromethyl and trifluoromethoxy, or when the dotted line represents a bond, then R5 may also be H.
2. The compound of formula (I) as defined in claim 1, wherein the dotted line is a bond and R1, R4 and R5 are H and R2 and R3 are F.
3. The compound of formula (I) as defined in claim 1, wherein R1 and R4 are H and R2, R3 and R5 are F.
4. The compound of formula (I) as defined in claim 1, wherein R1 and R4 are H, R2 and R3 are F, and R5 is methyl.
5. The compound of formula (I) as defined in claim 1, wherein the compound is 6,7-difluoro-1-methyl-3,4-dihydroisoquinoline or a pharmaceuti-cally acceptable salt thereof.
6. The compound of formula (I) as defined in claim 1, wherein the compound is 1-methyl-4,6,7-trifluoro-3,4-dihydroisoquinoline or a pharmaceuti-cally acceptable salt thereof.
7. The compound of formula (1) as defined in claim 1, wherein the compound is 4,6,7-trifuoro-1-methyl-1,2,3,4-tetrahydroisoquinoline or a phar-maceutically acceptable salt thereof.
8. A pharmaceutical composition comprising one or more compounds of formula (I) as defined in any one of claims 1 to 7, or a stereoisomer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier and suitable excipients.
9. The compound of formula (1) as defined in any one of claims 1 to 7, or a stereoisomer or pharmaceutically acceptable salt thereof for use as a medicament.
10. The compound of formula (1) as defined in any one of claims 1 to 7, or a stereoisomer or pharmaceutically acceptable salt thereof for use in the treatment of a disease selected from the group consisting of Alzheimer's disease, Parkinson's disease, depression, hyperactivity, narcolepsy and drug addiction, alcoholism, anorexia and bulimia.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10397511.6 | 2010-08-11 | ||
EP10397511A EP2420237A1 (en) | 2010-08-11 | 2010-08-11 | Fluorinated derivatives of endogenous isoquinolines for use in the treatment of diseases mediated through endogenous isoquinoline pathways |
PCT/FI2011/050707 WO2012020170A1 (en) | 2010-08-11 | 2011-08-10 | Novel 6,7-disubstituted-isoquinoline derivatives and their use |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2808016A1 CA2808016A1 (en) | 2012-02-16 |
CA2808016C true CA2808016C (en) | 2018-10-30 |
Family
ID=43827823
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2808016A Active CA2808016C (en) | 2010-08-11 | 2011-08-10 | 6,7-disubstituted-isoquinoline derivatives and their use |
Country Status (16)
Country | Link |
---|---|
US (1) | US8815898B2 (en) |
EP (2) | EP2420237A1 (en) |
CN (1) | CN103179971A (en) |
CA (1) | CA2808016C (en) |
CY (1) | CY1116588T1 (en) |
DK (1) | DK2603217T3 (en) |
ES (1) | ES2541401T3 (en) |
HR (1) | HRP20150668T1 (en) |
HU (1) | HUE026482T2 (en) |
PL (1) | PL2603217T3 (en) |
PT (1) | PT2603217E (en) |
RS (1) | RS54081B1 (en) |
RU (1) | RU2636938C2 (en) |
SI (1) | SI2603217T1 (en) |
SM (1) | SMT201500160B (en) |
WO (1) | WO2012020170A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105585527B (en) * | 2015-12-17 | 2018-06-26 | 浙江工业大学 | 2- (3,4- dihydro-isoquinolines -1 (2H)-subunit) cyanide compounds and its application |
CN105461626B (en) * | 2015-12-17 | 2018-05-08 | 浙江工业大学 | Aromatic ring or condensed hetero ring connection 3,4- dihydroisoquinoliness conjugated structure compounds and its application |
FI130627B (en) | 2021-03-31 | 2023-12-18 | Equinorm Ltd | Novel heterocyclic compounds and their use |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2716548B2 (en) * | 1989-11-01 | 1998-02-18 | 雅昭 廣部 | Parkinsonism prevention / treatment agent |
DE4041482A1 (en) | 1990-12-22 | 1992-06-25 | Boehringer Ingelheim Kg | NEW PHARMACEUTICAL USE OF CARBOCYCLIC AND HETEROCYCLICALLY ANNELATED DIHYDROPYRIDINE |
US5491148A (en) | 1991-04-26 | 1996-02-13 | Syntex (U.S.A.) Inc. | Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists |
US5246943A (en) * | 1992-05-19 | 1993-09-21 | Warner-Lambert Company | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties |
ES2230618T3 (en) | 1996-09-27 | 2005-05-01 | Aventis Pharmaceuticals Inc. | PICTET-SPENGLER REACTION FOR SYNTHESIS OF TETRAHYDROISOQUINOLINS AND RELATED HETEROCICLICAL COMPOUNDS. |
EP1246805A1 (en) * | 1999-11-03 | 2002-10-09 | Albany Molecular Research, Inc. | 4-phenyl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
WO2006035280A1 (en) | 2004-09-27 | 2006-04-06 | Ranbaxy Laboratories Limited | 3,4-dihydroisoquinoline compounds as muscrinic receptor antagonists for the treatment of respiratory, urinary and gastrointestinal diseases |
US20060111393A1 (en) * | 2004-11-22 | 2006-05-25 | Molino Bruce F | 4-Phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
EP2090576A1 (en) * | 2008-02-01 | 2009-08-19 | Merz Pharma GmbH & Co.KGaA | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators |
-
2010
- 2010-08-11 EP EP10397511A patent/EP2420237A1/en not_active Withdrawn
-
2011
- 2011-08-10 RS RS20150436A patent/RS54081B1/en unknown
- 2011-08-10 DK DK11770473.4T patent/DK2603217T3/en active
- 2011-08-10 CA CA2808016A patent/CA2808016C/en active Active
- 2011-08-10 US US13/814,987 patent/US8815898B2/en active Active
- 2011-08-10 WO PCT/FI2011/050707 patent/WO2012020170A1/en active Application Filing
- 2011-08-10 HU HUE11770473A patent/HUE026482T2/en unknown
- 2011-08-10 SI SI201130527T patent/SI2603217T1/en unknown
- 2011-08-10 ES ES11770473.4T patent/ES2541401T3/en active Active
- 2011-08-10 PT PT117704734T patent/PT2603217E/en unknown
- 2011-08-10 CN CN2011800490170A patent/CN103179971A/en active Pending
- 2011-08-10 PL PL11770473T patent/PL2603217T3/en unknown
- 2011-08-10 EP EP11770473.4A patent/EP2603217B1/en active Active
- 2011-08-10 RU RU2013110377A patent/RU2636938C2/en not_active Application Discontinuation
-
2015
- 2015-06-19 HR HRP20150668TT patent/HRP20150668T1/en unknown
- 2015-07-02 CY CY20151100573T patent/CY1116588T1/en unknown
- 2015-07-03 SM SM201500160T patent/SMT201500160B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CY1116588T1 (en) | 2017-03-15 |
DK2603217T3 (en) | 2015-07-13 |
WO2012020170A1 (en) | 2012-02-16 |
US20130137719A1 (en) | 2013-05-30 |
SI2603217T1 (en) | 2015-08-31 |
ES2541401T3 (en) | 2015-07-20 |
SMT201500160B (en) | 2015-09-07 |
RU2013110377A (en) | 2014-09-20 |
EP2420237A1 (en) | 2012-02-22 |
HUE026482T2 (en) | 2016-06-28 |
PT2603217E (en) | 2015-08-26 |
RS54081B1 (en) | 2015-10-30 |
US8815898B2 (en) | 2014-08-26 |
CN103179971A (en) | 2013-06-26 |
EP2603217A1 (en) | 2013-06-19 |
RU2636938C2 (en) | 2017-11-29 |
CA2808016A1 (en) | 2012-02-16 |
PL2603217T3 (en) | 2015-09-30 |
HRP20150668T1 (en) | 2015-09-11 |
EP2603217B1 (en) | 2015-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW509667B (en) | Bicyclo [2.2.1] heptanes and related compounds | |
JP6880127B2 (en) | Synthesis of polycyclic carbamoylpyridone compounds | |
RU2659784C2 (en) | (n-substituted imidazole)-carboxylic ester chiral compound containing ether side chain, preparation method and application | |
AU2009289329A1 (en) | Triazole derivatives and their use as nicotinic acetylcholine receptor modulators | |
JP2008521805A (en) | Cardiotonic compounds having inhibitory activity against β-adrenergic receptors and phosphodiesterases | |
JP2015527336A (en) | Piperazinotriazole compounds, process for producing the same and pharmaceutical use | |
MX2015002602A (en) | Imidazoline derivatives, preparation methods thereof, and their applications in medicine. | |
CA2666373A1 (en) | Heterocyclic compounds useful as anabolic agents for livestock animals | |
CA2808016C (en) | 6,7-disubstituted-isoquinoline derivatives and their use | |
US8222454B2 (en) | Process for preparing optical pure milnacipran and its pharmaceutically accepted salts | |
CN102702067B (en) | Novel intermediate for synthesizing silodosin as well as preparation method and purpose of novel intermediate | |
JP2008542386A (en) | MAO-B inhibitor useful for the treatment of obesity | |
US6828345B2 (en) | O-substituted 6-methyltramadol derivatives | |
ITMI20101224A1 (en) | NEW PROCESS FOR THE PREPARATION OF TAPENTADOL AND ITS INTERMEDIATES. | |
HU225102B1 (en) | Substituted aminomethyl-phenyl-cyclohexane derivatives, process for their preparation and pharmaceutical compositions containing them | |
US6890959B2 (en) | Aminomethyl-phenyl-cyclohexanone derivatives | |
CN108349872A (en) | The synthesis of terphenyl compounds | |
US20120289744A1 (en) | Process for preparing optically pure milnacipran and its pharmaceutically acceptable salts | |
WO1998042713A1 (en) | 2,3-DIHYDROFURO[3,2-b]PYRIDIN, PREPARATION AND APPLICATION THEREOF IN THERAPY | |
JP3444495B2 (en) | 2-aminopyridine containing a condensed ring substituent as a nitric oxide synthase inhibitor | |
WO2008019572A1 (en) | Meptazinol biligand derivatives and/or their salts, preparation method and uses thereof | |
WO2021033729A1 (en) | Salt and crystal form of compound having agonistic activity to s1p5 receptor | |
JP2006525350A (en) | Quinoline 3-aminochroman derivative | |
EP2784077B1 (en) | Norepinephrine and selective serotonin receptor blocker and use thereof | |
US9271979B2 (en) | Deuterium-enriched pyrimidine compounds and derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20160803 |